Sanofi Challenges Novartis’ Leadership in Radiopharma with 'Clinically Significant' Data on Pancreatic Tumors

Sanofi Challenges Novartis’ Leadership in Radiopharma with ‘Clinically Significant’ Data on Pancreatic Tumors

Sanofi Challenges Novartis’ Leadership in Radiopharma with 'Clinically Significant' Data on Pancreatic Tumors